[Cardiovascular diseases in Switzerland - Prevalence and care].

Q4 Medicine Praxis Pub Date : 2024-03-01
Thomas Rosemann, Agnès Bachofner, Oliver Strehle
{"title":"[Cardiovascular diseases in Switzerland - Prevalence and care].","authors":"Thomas Rosemann, Agnès Bachofner, Oliver Strehle","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular diseases (CVD) represent a significant health problem worldwide and in Switzerland. Despite preventive measures and advances in treatment, cardiovascular diseases still lead to a significant number of hospitalizations in Switzerland (133 000 in 2021) and are for responsible for almost 1/3 of all deaths (19 600 in 2021). Emergency care for acute cardiovascular events now has a very high standard in Switzerland compared to other countries. However, there is a large discrepancy between evidence and daily practice (evidence-performance gap) in cardiovascular risk factor control, because a large percentage of patients do not achieve the goals of the guideline recommendations: 55% of hypertensives, 81% of patients with elevated LDL cholesterol and 44% of diabetics. In addition, 21% of people in Switzerland currently smoke, 42% are considered obese and 24% of people are sedentary. Therefore, primary and secondary prevention offers great potential for reducing the morbidity and mortality of cardiovascular diseases. Sub-optimal control of cardiovascular risk factors leads to preventable cardiovascular events and associated economic costs. Thus, cardiovascular diseases not only affect life expectancy, but also influence the years with reduced quality of life (disability-adjusted life years, DALY). In Switzerland, the main risk factors of cardiovascular diseases lead to a loss of 311 332 DALYs in total, 45 454 DALYs lost by hypertension, 64 445 DALYs lost due to hyperlipidema, 24 283 DALYs due to diabetes mellitus, 47 639 DALYs due to smoking, 21 170 DALYs lost by obesity)and 4 669 DALYs lost due to a lack of exercise. Assuming that one DALY is associated with a socioeconomic burden of CHF 99 417, the total socioeconomic cost of all cardiovascular diseases is 4% of gross domestic product (GDP). Furthermore, cardiovascular diseases caused a cost burden of CHF 27,8 billion in direct and indirect healthcare costs in 2021. Keywords: Cardiovascular diseases, hypertension, risk factors, prevention, healthcare costs, DALY, mortality.</p>","PeriodicalId":20494,"journal":{"name":"Praxis","volume":"113 3","pages":"57-66"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Praxis","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Cardiovascular diseases (CVD) represent a significant health problem worldwide and in Switzerland. Despite preventive measures and advances in treatment, cardiovascular diseases still lead to a significant number of hospitalizations in Switzerland (133 000 in 2021) and are for responsible for almost 1/3 of all deaths (19 600 in 2021). Emergency care for acute cardiovascular events now has a very high standard in Switzerland compared to other countries. However, there is a large discrepancy between evidence and daily practice (evidence-performance gap) in cardiovascular risk factor control, because a large percentage of patients do not achieve the goals of the guideline recommendations: 55% of hypertensives, 81% of patients with elevated LDL cholesterol and 44% of diabetics. In addition, 21% of people in Switzerland currently smoke, 42% are considered obese and 24% of people are sedentary. Therefore, primary and secondary prevention offers great potential for reducing the morbidity and mortality of cardiovascular diseases. Sub-optimal control of cardiovascular risk factors leads to preventable cardiovascular events and associated economic costs. Thus, cardiovascular diseases not only affect life expectancy, but also influence the years with reduced quality of life (disability-adjusted life years, DALY). In Switzerland, the main risk factors of cardiovascular diseases lead to a loss of 311 332 DALYs in total, 45 454 DALYs lost by hypertension, 64 445 DALYs lost due to hyperlipidema, 24 283 DALYs due to diabetes mellitus, 47 639 DALYs due to smoking, 21 170 DALYs lost by obesity)and 4 669 DALYs lost due to a lack of exercise. Assuming that one DALY is associated with a socioeconomic burden of CHF 99 417, the total socioeconomic cost of all cardiovascular diseases is 4% of gross domestic product (GDP). Furthermore, cardiovascular diseases caused a cost burden of CHF 27,8 billion in direct and indirect healthcare costs in 2021. Keywords: Cardiovascular diseases, hypertension, risk factors, prevention, healthcare costs, DALY, mortality.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[瑞士的心血管疾病--发病率和护理]。
导言:心血管疾病(CVD)是全球和瑞士的一个重大健康问题。尽管采取了预防措施并在治疗方面取得了进步,但心血管疾病仍导致瑞士大量患者住院治疗(2021年为13.3万人),并造成近1/3的死亡(2021年为1.96万人)。与其他国家相比,瑞士目前对急性心血管事件的紧急救治标准很高。然而,在心血管风险因素控制方面,证据与日常实践之间存在很大差距(证据与实践之间的差距),因为很大一部分患者没有达到指南建议的目标:55%的高血压患者、81%的低密度脂蛋白胆固醇升高患者和44%的糖尿病患者。此外,瑞士目前有 21% 的人吸烟,42% 的人肥胖,24% 的人久坐不动。因此,一级和二级预防为降低心血管疾病的发病率和死亡率提供了巨大潜力。心血管风险因素控制不佳会导致可预防的心血管事件和相关经济成本。因此,心血管疾病不仅会影响预期寿命,还会影响生活质量下降的年数(残疾调整生命年)。在瑞士,心血管疾病的主要风险因素共导致 311 332 个残疾调整生命年的损失,其中高血压导致 45 454 个残疾调整生命年的损失,高血脂导致 64 445 个残疾调整生命年的损失,糖尿病导致 24 283 个残疾调整生命年的损失,吸烟导致 47 639 个残疾调整生命年的损失,肥胖导致 21 170 个残疾调整生命年的损失,缺乏运动导致 4 669 个残疾调整生命年的损失。假设一个残疾调整寿命年的社会经济负担为 99 417 瑞士法郎,那么所有心血管疾病的社会经济总成本占国内生产总值(GDP)的 4%。此外,2021 年,心血管疾病造成的直接和间接医疗成本高达 278 亿瑞士法郎。关键词心血管疾病、高血压、风险因素、预防、医疗成本、残疾调整寿命年数、死亡率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Praxis
Praxis Medicine-Medicine (all)
CiteScore
0.40
自引率
0.00%
发文量
146
审稿时长
12 weeks
期刊最新文献
[Alzheimer's disease - system prepardeness in the context of new developments]. [Clinical management of patients with cavernous malformations of the central nervous system: an update and recommendations for clinical practice]. [Rabies and mobility: 2025 update]. [Ultrasound-guided synovial biopsy]. [Uncommon Yet Severe: Metabolic Acidosis from Concurrent Use of Paracetamol and Flucloxacillin].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1